LYNDSEY O'ROURKE: Open Payments
NPI 1801367743 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,765 in 212 payments from 21 companies in 2025. Trend: 2023 $3,767 · 2024 $5,096 · 2025 $6,765
Food & beverage: $5,520Consulting: $1,245
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $1,888 |
| ABBVIE INC. | 56 | $1,387 |
| Gilead Sciences, Inc. | 20 | $487 |
| Lilly USA, LLC | 12 | $429 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $407 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $377 |
| Madrigal Pharmaceuticals | 10 | $339 |
| Phathom Pharmaceuticals, Inc. | 8 | $223 |
| QOL Medical, LLC | 17 | $220 |
| Regeneron Healthcare Solutions, Inc. | 8 | $205 |
Products named: TREMFYA, SKYRIZI, XIFAXAN, REZDIFFRA, ENTYVIO, OMVOH, DUPIXENT, RINVOQ.
Industry payments across CO — which companies pay providers there.
